CAPR - Company ID 0001133869
The table below shows CAPRICOR THERAPEUTICS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $22.27M | $25.18M | $2.55M | $244.90K | $310.25K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $84.45M | $49.97M | $36.45M | $21.82M | $13.57M | $8.46M |
| SG&A |
CAPRICOR THERAPEUTICS, INC. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $22.27M in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $4.00M (FY 2016) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $23.69M |
| $14.87M |
| $12.81M |
| $10.43M |
| $7.61M |
| $5.54M |
| Operating income | -$108.14M | -$42.56M | -$24.08M | -$29.70M | -$20.94M | -$13.69M |
| Income tax | $1.60K | $1.60K | - | - | - | - |
| Net income | -$105.04M | -$40.47M | -$22.29M | -$29.02M | -$20.02M | -$13.66M |
| EPS (diluted) | -$2.26 | -$1.15 | -$0.83 | -$1.18 | -$0.87 | -$0.88 |